Navigation Links
Renaissance in new drugs for rare diseases
Date:5/15/2013

Once famously described as "orphan diseases, too small to be noticed, too small to be funded" in the Hollywood drama "Lorenzo's Oil," rare diseases are getting unprecedented attention today among drug manufacturers, who are ramping up research efforts and marketing new medicines that promise fuller lives for children and other patients with these heartbreaking conditions.

That's the finding of a major examination, published in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society, and reaches more than 138,000 scientists, policymakers, educators and others. Written by Senior Editor Lisa Jarvis after months of interviews with patients, parents, pharmaceutical industry officials and others, the story focuses on the status of new drugs for rare diseases. Those 7,000 conditions affect 200,000 patients or fewer.

Jarvis describes how a combination of factors coalesced to foster a renaissance in drug development for rare diseases. Smaller drug companies, for instance, have shown that it is possible to make big profits from sales of medicines for rare diseases, and larger companies have taken notice. Patient advocacy groups are another driving force. They are directly funding some research and drawing attention and dollars for research. Deeper insights into the genetics of rare diseases and federal legislation extending patent protection for treatments also have helped.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Renaissance in new drugs for rare diseases: Report in worlds largest scientific socity magazine
2. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
3. Nanopills release drugs directly from the inside of cells
4. Genetic variation in East Asians found to explain resistance to cancer drugs
5. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
6. Internet and new drugs: A challenge for public health
7. Study raises questions about use of anti-epilepsy drugs in newborns
8. Drugs from lizard saliva reduces the cravings for food
9. A new method detects traces of veterinary drugs in baby food
10. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
11. MIT-designed cooler preserves tuberculosis drugs, records doses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
Breaking Biology Technology: